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melioidosis is considered highly endemic. By contrast, South Asia is
predicted to bear 44% of the overall burden, because large popula-
tions live in areas contaminatedwithB. pseudomallei. Our estimates
suggest that melioidosis is severely underreported in the 45 coun-
tries in which it is known to be endemic and that melioidosis is
likely endemic in a further 34 countries which have never reported
the disease.
The large numbers of estimated cases and fatalities emphasise
that the disease warrants renewed attention from public health
ofﬁcials and policy makers.
http://dx.doi.org/10.1016/j.ijid.2016.02.103
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Abstract: Largely due to its recognition as a biological
threat agent, current knowledge on melioidosis, caused by the
Gram-negative bacterium Burkholderia pseudomallei, has increased
tremendously in the last decade. In this talk, recent insights will be
given on our understanding on the molecular characterization of B.
pseudomallei and the immunology of melioidosis.
The genome of B. pseudomallei is composed of two chromo-
somes of which the largest part represents the B. pseudomallei
core genome, whereas the remaining accessory genome has been
associatedwith bacterial virulence. Virulence factors, most notably
quorum sensing, type III secretion system, lipopolysaccharide and
other surface polysaccharides, ﬂagella and various factors essential
for the intracellular life cycle of B. pseudomallei, have been further
characterized. These so calledmicroorganism associatedmolecular
patterns (MAMPs) are recognized by pattern recognition receptors
(PRRs) such as Toll-like receptors and NOD-like receptors (NLRs).
The neutrophils play a critical in host defense, which is initiated
by the TLRs. The proinﬂammatory immune response – including
the activation of coagulation – is further ignited by the release of
various damage associated molecular patterns (DAMPs) such as
calprotectin and the nucleosomes which are also recognized by
PRRs.
Severe melioidosis can probably be seen as the clinical manifes-
tation of a PRR mediated dysregulation of the immune response to
invading B. pseudomallei. B. pseudomallei employs numerous tactics
to evade the immune response. Studies on host–pathogen interac-
tions in melioidosis have identiﬁed a whole range of potential new
treatment targets which will be discussed.
http://dx.doi.org/10.1016/j.ijid.2016.02.104
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Abstract: For many years it has been clear that melioidosis is
endemic in parts of SE Asia and northern Australia, but over the
past 25 years, the melioidosis iceberg has been emerging. Within
known endemic areas, cases are being recognized with increasing
frequency. New endemic areas are also being identiﬁed, partic-
ularly in Africa and the Americas, but also in Asia. In Laos, for
example, the ﬁrst case of melioidosis was diagnosed as recently
as 1999, but since then more than 900 cases of culture-positive
melioidosis have been diagnosed in a single laboratory, although
this is just the tip of a national iceberg.
Worldwide, the disease undoubtedly remains under-diagnosed,
especially in the Indian sub-continent. The two main barriers to
the diagnosis of the disease, which has its biggest impact on the
rural poor, are access to high quality diagnostics, and the lack of
awareness and familiarity of clinical and laboratory staff. Clini-
cal diagnosis is difﬁcult due to the protean manifestations of the
disease. Where microbiology laboratories exist, the mainstay of
diagnosis remains culture. The organism is easy to grow as long
as the site of infection can be sampled, but laboratory technicians
unfamiliar with the organism may discard it as a contaminant.
An important clue is resistance to aminoglycosides and colistin
combined with susceptibility to co-amoxiclav, although regional
variantshave recentlybeendescribed. Latexagglutinationor lateral
ﬂow tests are useful for screening suspect isolates, and the latter
may be used for rapid diagnosis directly on clinical samples.Molec-
ular tests such as PCR have not yet found a role in routine diagnosis.
Available serological tests also lack sensitivity and speciﬁcity.
Current treatment regimens, comprising an initial parenteral
phase with either ceftazidime or a carbapenem followed by a pro-
longedoral eradicationphasewithco-trimoxazoleor co-amoxiclav,
are based on strong evidence from a series of clinical trials
conducted in Thailand. Several questions remain unanswered,
however, such as the optimal duration of each phase and the role
of adjunctive treatment.
Even with optimal antibiotic therapy the mortality in develop-
ing countries remains disappointingly high.
http://dx.doi.org/10.1016/j.ijid.2016.02.105
